You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMedroxyprogesterone acetate
Accession NumberDB00603  (APRD00627)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionMedroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. [Wikipedia]
Structure
Thumb
Synonyms
(6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
17-Acetoxy-6alpha-methylprogesterone
17-Acetoxy-6α-methylprogesterone
17alpha-Hydroxy-6alpha-methylprogesterone acetate
17α-hydroxy-6α-methylprogesterone acetate
6-alpha-Methyl-17-alpha-acetoxyprogesterone
6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate
6alpha-Methyl-17-acetoxy progesterone
6alpha-Methyl-17alpha-hydroxyprogesterone acetate
6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate
6α-Methyl-17-acetoxy progesterone
6α-Methyl-17α-hydroxyprogesterone acetate
Medroxyacetate progesterone
Medroxyprogesterone 17-acetate
Medroxyprogesterone acetate
Methylacetoxyprogesterone
Metigestrona
MPA
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Depo-proverainjection, suspension150 mg/mLintramuscularPharmacia And Upjohn Company Llc1992-10-29Not applicableUs
Depo-proverainjection, suspension150 mg/mLintramuscularA S Medication Solutions Llc1992-10-29Not applicableUs
Depo-proverainjection, suspension150 mg/mLintramuscularPharmacia And Upjohn Company Llc1992-10-29Not applicableUs
Depo-proverainjection, suspension150 mg/mLintramuscularA S Medication Solutions Llc1992-10-29Not applicableUs
Depo-proverainjection, suspension400 mg/mLintramuscularPharmacia And Upjohn Company Llc1960-11-01Not applicableUs
Depo-proverainjection, suspension400 mg/mLintramuscularPhysicians Total Care, Inc.1995-01-13Not applicableUs
Depo-provera Sterile Aqueous Suspension 150 mg/mlsuspension150 mgintramuscularPfizer Canada Inc1995-12-31Not applicableCanada
Depo-provera Sterile Aqueous Suspension 50 mg/mlsuspension50 mgintramuscularPfizer Canada Inc1960-12-31Not applicableCanada
Depo-subq Proverainjection, suspension104 mg/.65mLsubcutaneousPharmacia and Upjohn Company2005-05-02Not applicableUs
Dom-medroxyprogesteronetablet2.5 mgoralDominion Pharmacal2003-05-13Not applicableCanada
Dom-medroxyprogesteronetablet5 mgoralDominion Pharmacal2003-05-13Not applicableCanada
Dom-medroxyprogesteronetablet10 mgoralDominion Pharmacal2003-05-13Not applicableCanada
Gen-medroxy Tablet 10mgtablet10 mgoralGenpharm Ulc1997-03-122010-08-04Canada
Gen-medroxy Tablet 2.5mgtablet2.5 mgoralGenpharm Ulc1997-03-122010-08-04Canada
Gen-medroxy Tablet 5mgtablet5 mgoralGenpharm Ulc1997-03-122010-08-04Canada
Medroxy-2.5tablet2.5 mgoralPro Doc Limitee2004-07-21Not applicableCanada
Medroxy-5tablet5 mgoralPro Doc Limitee2004-07-21Not applicableCanada
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularREMEDYREPACK INC.2014-12-31Not applicableUs
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularPhysicians Total Care, Inc.2005-03-31Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralPhysicians Total Care, Inc.1994-07-06Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.1959-06-03Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralAvera Mc Kennan Hospital2015-04-30Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralGreenstone LLC1959-06-03Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralCardinal Health1959-06-03Not applicableUs
Medroxyprogesterone Acetatetablet2.5 mg/1oralPhysicians Total Care, Inc.1995-04-24Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralREMEDYREPACK INC.2011-06-07Not applicableUs
Medroxyprogesterone Acetatetablet2.5 mg/1oralAmerican Health Packaging2012-01-272015-12-31Us
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularGreenstone LLC1992-10-29Not applicableUs
Medroxyprogesterone Acetatetablet2.5 mg/1oralPd Rx Pharmaceuticals, Inc.1959-06-03Not applicableUs
Medroxyprogesterone Acetatetablet2.5 mg/1oralGreenstone LLC1959-06-03Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralPhysicians Total Care, Inc.1995-09-19Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralPd Rx Pharmaceuticals, Inc.1959-06-03Not applicableUs
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularGreenstone LLC1992-10-29Not applicableUs
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularREMEDYREPACK INC.2013-05-30Not applicableUs
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularA S Medication Solutions Llc1992-10-29Not applicableUs
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularPreferred Pharmaceuticals, Inc1992-10-29Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralGreenstone LLC1959-06-03Not applicableUs
Medroxyprogesterone Acetate Injectable Suspension USPsuspension150 mgintramuscularSandoz Canada Incorporated2009-02-05Not applicableCanada
Meprogesttablet2.5 mgoralPfizer Canada IncNot applicableNot applicableCanada
Meprogesttablet5 mgoralPfizer Canada IncNot applicableNot applicableCanada
Meprogesttablet10 mgoralPfizer Canada IncNot applicableNot applicableCanada
Nu-medroxytablet2.5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-medroxytablet5 mgoralNu Pharm IncNot applicableNot applicableCanada
Penta-medroxyprogesterone Tabletstablet2.5 mgoralPentapharm Ltd.1998-10-092004-07-30Canada
Penta-medroxyprogesterone Tabletstablet5 mgoralPentapharm Ltd.1998-10-232004-07-30Canada
Penta-medroxyprogesterone Tabletstablet10 mgoralPentapharm Ltd.1998-10-092004-07-30Canada
PMS-medroxyprogesteronetablet10 mgoralPharmascience Inc2002-11-12Not applicableCanada
PMS-medroxyprogesteronetablet2.5 mgoralPharmascience Inc2002-11-12Not applicableCanada
PMS-medroxyprogesteronetablet5 mgoralPharmascience Inc2002-11-12Not applicableCanada
Proclimtablet2.5 mgoralFournier Pharma Inc1999-05-282000-11-14Canada
Proclimtablet5 mgoralFournier Pharma Inc1999-05-282000-11-14Canada
Proclimtablet10 mgoralFournier Pharma Inc1999-05-282000-11-14Canada
Proveratablet10 mg/1oralPharmacia and Upjohn Company1959-06-03Not applicableUs
Proveratablet2.5 mg/1oralPharmacia and Upjohn Company1959-06-03Not applicableUs
Proveratablet5 mg/1oralPharmacia and Upjohn Company1959-06-03Not applicableUs
Provera 100mg Tabletstablet100 mgoralPfizer Canada Inc1968-12-312012-02-13Canada
Provera 10mg Tabletstablet10 mgoralPfizer Canada Inc1987-12-31Not applicableCanada
Provera 2.5mg Tabletstablet2.5 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Provera 5mg Tabletstablet5 mgoralPfizer Canada Inc1961-12-31Not applicableCanada
Provera Pak 10mg Tabletstablet10 mgoralPfizer Canada Inc1993-12-312014-04-04Canada
Provera Pak 5mg Tabletstablet5 mgoralPfizer Canada Inc1993-12-312014-03-26Canada
Ratio-mpatablet5 mgoralRatiopharm Inc Division Of Teva Canada Limited1996-07-172008-08-01Canada
Ratio-mpatablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited1996-07-172008-08-01Canada
Ratio-mpatablet2.5 mgoralRatiopharm Inc Division Of Teva Canada Limited1996-07-172008-08-01Canada
Teva-medroxyprogesteronetablet10 mgoralTeva Canada Limited1997-01-07Not applicableCanada
Teva-medroxyprogesteronetablet2.5 mgoralTeva Canada Limited1997-01-07Not applicableCanada
Teva-medroxyprogesteronetablet5 mgoralTeva Canada Limited1997-01-07Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-medroxytablet10 mgoralApotex Inc2007-01-10Not applicableCanada
Apo-medroxytablet100 mgoralApotex Inc2005-08-04Not applicableCanada
Apo-medroxy Tabletstablet2.5 mgoralApotex Inc2002-04-22Not applicableCanada
Apo-medroxy Tabletstablet5 mgoralApotex Inc2002-04-22Not applicableCanada
Medroxyprogesterone Acetatetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2012-02-13Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralAidarex Pharmaceuticals LLC1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralBarr Laboratories Inc.1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralREMEDYREPACK INC.2014-01-09Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralBlenheim Pharmacal, Inc.2010-05-20Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralReady Meds1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet2.5 mg/1oralAidarex Pharmaceuticals LLC1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralbryant ranch prepack1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet2.5 mg/1oralBarr Laboratories Inc.1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralA S Medication Solutions Llc1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet2.5 mg/1oralA S Medication Solutions1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralBlenheim Pharmacal, Inc.2010-05-20Not applicableUs
Medroxyprogesterone Acetatetablet2.5 mg/1oralReady Meds1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralAidarex Pharmaceuticals LLC1996-12-03Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralBarr Laboratories Inc.1996-12-03Not applicableUs
Medroxyprogesterone Acetatetablet2.5 mg/1oralbryant ranch prepack1996-12-04Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralA S Medication Solutions Llc1996-12-03Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralDispensing Solutions, Inc.2011-01-18Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralRebel Distributors Corp.1996-08-09Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Medroxyprogesterone Acetateinjection, suspension150 mg/mLintramuscularTeva Parenteral Medicines, Inc.2004-09-14Not applicableUs
Medroxyprogesterone Acetatetablet5 mg/1oralbryant ranch prepack1996-12-03Not applicableUs
Medroxyprogesterone Acetatetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2011-01-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Depo-subq provera 104Not Available
Brand mixtures
NameLabellerIngredients
PremphaseWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
PremplusPfizer Canada Inc
Premplus CyclePfizer Canada Inc
PremproWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
SaltsNot Available
Categories
UNIIC2QI4IOI2G
CAS number71-58-9
WeightAverage: 386.5244
Monoisotopic: 386.245709576
Chemical FormulaC24H34O4
InChI KeyInChIKey=PSGAAPLEWMOORI-PEINSRQWSA-N
InChI
InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
IUPAC Name
(1S,2R,8S,10R,11S,14R,15S)-14-acetyl-2,8,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl acetate
SMILES
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[[email protected]](C)C2=CC(=O)CC[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • Steroid ester
  • 20-oxosteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Alpha-acyloxy ketone
  • Acetate salt
  • Cyclic ketone
  • Ketone
  • Carboxylic acid ester
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.
PharmacodynamicsMedroxyprogesterone acetate is a synthetic progestin more potent than progesterone.
Mechanism of actionProgestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.
Related Articles
AbsorptionRapidly absorbed from GI tract
Volume of distributionNot Available
Protein binding90%
Metabolism

Hepatic

SubstrateEnzymesProduct
Medroxyprogesterone acetate
6β-HydroxymedroxyprogesteroneDetails
Medroxyprogesterone acetate
2β-HydroxymedroxyprogesteroneDetails
Medroxyprogesterone acetate
1β-HydroxymedroxyprogesteroneDetails
Route of eliminationFollowing oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates.
Half life50 days
Clearance
  • 64110 +/- 42662 mL/min [postmenopausal women under fasting conditions with a single Dose of 2 × 10 mg]
  • 74123 +/- 35126 mL/min [postmenopausal women under fasting conditions with a single Dose of 8 × 2.5 mg]
  • 41963 +/- 38402 mL/min [postmenopausal women following daily administration of one PROVERA 10 mg tablet for 7 days]
ToxicitySide effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9617
Caco-2 permeable+0.651
P-glycoprotein substrateSubstrate0.6107
P-glycoprotein inhibitor IInhibitor0.9149
P-glycoprotein inhibitor IIInhibitor0.7016
Renal organic cation transporterNon-inhibitor0.7753
CYP450 2C9 substrateNon-substrate0.8642
CYP450 2D6 substrateNon-substrate0.908
CYP450 3A4 substrateSubstrate0.7744
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.8907
CYP450 2D6 inhibitorNon-inhibitor0.9532
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8095
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.899
Ames testNon AMES toxic0.9775
CarcinogenicityNon-carcinogens0.9273
BiodegradationNot ready biodegradable0.9354
Rat acute toxicity1.8121 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9429
hERG inhibition (predictor II)Non-inhibitor0.7761
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Barr laboratories inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Usl pharma inc
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg
Injection, suspensionintramuscular400 mg/mL
Suspensionintramuscular150 mg
Suspensionintramuscular50 mg
Injection, suspensionsubcutaneous104 mg/.65mL
Injection, suspensionintramuscular150 mg/mL
Kit
Kit; tabletoral
Tablet, sugar coatedoral
Tabletoral10 mg/1
Tabletoral2.5 mg/1
Tabletoral5 mg/1
Tabletoral2.5 mg
Tabletoral5 mg
Tabletoral10 mg
Prices
Unit descriptionCostUnit
Depo-Provera 400 mg/ml Suspension 2.5ml Vial201.13USD vial
Depo-subq provera 104 syringe108.17USD syringe
Depo-provera 400 mg/ml vial96.7USD ml
Depo-Provera 150 mg/ml Suspension 1ml Syringe94.58USD syringe
MedroxyPROGESTERone Acetate 150 mg/ml Suspension 1ml Syringe60.56USD syringe
MedroxyPROGESTERone Acetate 150 mg/ml Suspension 1ml Vial55.17USD vial
Depo-Provera 150 mg/ml31.02USD ml
Medroxyprogesterone Acetate 150 mg/ml23.05USD ml
Medroxyprogesterone ace powder18.97USD g
Depo-Provera 50 mg/ml6.01USD ml
Provera 10 mg tablet2.03USD tablet
Provera 5 mg tablet1.57USD tablet
Provera 100 mg Tablet1.41USD tablet
Provera 2.5 mg tablet1.15USD tablet
Apo-Medroxy 100 mg Tablet0.96USD tablet
Provera 10 mg Tablet0.73USD tablet
MedroxyPROGESTERone Acetate 10 mg tablet0.51USD tablet
MedroxyPROGESTERone Acetate 5 mg tablet0.48USD tablet
MedroxyPROGESTERone Acetate 2.5 mg tablet0.43USD tablet
Medroxyprogesterone 10 mg tablet0.4USD tablet
Provera 5 mg Tablet0.36USD tablet
Medroxyprogesterone 5 mg tablet0.33USD tablet
Apo-Medroxy 10 mg Tablet0.33USD tablet
Novo-Medrone 10 mg Tablet0.33USD tablet
Medroxyprogesterone 2.5 mg tablet0.32USD tablet
Provera 2.5 mg Tablet0.18USD tablet
Apo-Medroxy 5 mg Tablet0.16USD tablet
Novo-Medrone 5 mg Tablet0.16USD tablet
Apo-Medroxy 2.5 mg Tablet0.08USD tablet
Novo-Medrone 2.5 mg Tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2409059 No2006-04-182021-04-25Canada
US6495534 No2000-05-152020-05-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point214.5 °CPhysProp
water solubility22.2mg/LNot Available
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00221 mg/mLALOGPS
logP3.42ALOGPS
logP4.13ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)17.82ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area60.44 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity107.81 m3·mol-1ChemAxon
Polarizability44.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Klaus ANNEN, Thomas Linz, Karl-Heinz Neff, Rolf Bohlmann, Henry Laurent, “PROCESS FOR PREPARING 17ALPHA-ACETOXY-6-METHYLENEPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE AND MEGESTROL ACETATE.” U.S. Patent US20090012321, issued January 08, 2009.

US20090012321
General References
  1. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH: Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1-2):171-80. [PubMed:19434889 ]
  2. Lenco W, Mcknight M, Macdonald AS: Effects of cortisone acetate, methylprednisolone and medroxyprogesterone on wound contracture and epithelization in rabbits. Ann Surg. 1975 Jan;181(1):67-73. [PubMed:1119869 ]
External Links
ATC CodesG03AC06G03FA12G03DA02G03AA08L02AB02G03FB06
AHFS Codes
  • 68:32.00
PDB EntriesNot Available
FDA labelDownload (1.2 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Medroxyprogesterone acetate.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Medroxyprogesterone acetate.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Medroxyprogesterone acetate.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Medroxyprogesterone acetate.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Medroxyprogesterone acetate.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Medroxyprogesterone acetate.
AmiodaroneThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Amiodarone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Medroxyprogesterone acetate.
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Medroxyprogesterone acetate.
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Medroxyprogesterone acetate.
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medroxyprogesterone acetate.
AprepitantThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Aprepitant.
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Medroxyprogesterone acetate.
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Medroxyprogesterone acetate.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Medroxyprogesterone acetate.
AtazanavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Atomoxetine.
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Medroxyprogesterone acetate.
BevacizumabBevacizumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.
BexaroteneThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bexarotene.
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medroxyprogesterone acetate.
BoceprevirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bosentan.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Medroxyprogesterone acetate.
C1 Esterase Inhibitor (Human)Medroxyprogesterone acetate may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Medroxyprogesterone acetate may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medroxyprogesterone acetate.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
CarbamazepineThe metabolism of Medroxyprogesterone acetate can be increased when combined with Carbamazepine.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Medroxyprogesterone acetate.
CeritinibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ceritinib.
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Medroxyprogesterone acetate.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Medroxyprogesterone acetate.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Medroxyprogesterone acetate.
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Medroxyprogesterone acetate.
ClarithromycinThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Clemastine.
ClotrimazoleThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Cobicistat.
ConivaptanThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Medroxyprogesterone acetate.
CyclosporineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Cyclosporine.
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medroxyprogesterone acetate.
DabrafenibThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dabrafenib.
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Medroxyprogesterone acetate.
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Medroxyprogesterone acetate.
DarunavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Delavirdine.
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Medroxyprogesterone acetate.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
DexamethasoneThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dexamethasone.
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Medroxyprogesterone acetate.
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Medroxyprogesterone acetate.
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Medroxyprogesterone acetate.
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Medroxyprogesterone acetate.
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Medroxyprogesterone acetate.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
DigoxinDigoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
DihydroergotamineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Diltiazem.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medroxyprogesterone acetate.
DoxycyclineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Medroxyprogesterone acetate.
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Medroxyprogesterone acetate.
EdoxabanThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Medroxyprogesterone acetate.
EfavirenzThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Efavirenz.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medroxyprogesterone acetate.
EnzalutamideThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Eslicarbazepine acetate.
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Medroxyprogesterone acetate.
EtravirineThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Medroxyprogesterone acetate.
FluconazoleThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Fluconazole.
FluvoxamineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Medroxyprogesterone acetate.
FosamprenavirThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Medroxyprogesterone acetate can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Fusidic Acid.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Medroxyprogesterone acetate.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Medroxyprogesterone acetate.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Medroxyprogesterone acetate.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Medroxyprogesterone acetate.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Medroxyprogesterone acetate.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Medroxyprogesterone acetate.
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Medroxyprogesterone acetate.
HirulogThe therapeutic efficacy of Hirulog can be decreased when used in combination with Medroxyprogesterone acetate.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Medroxyprogesterone acetate.
IdelalisibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Imatinib.
IndinavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Medroxyprogesterone acetate.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Medroxyprogesterone acetate.
IsavuconazoniumThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ketoconazole.
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Medroxyprogesterone acetate.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Medroxyprogesterone acetate.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Medroxyprogesterone acetate.
LopinavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Lopinavir.
LovastatinThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Luliconazole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate.
MifepristoneThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Medroxyprogesterone acetate.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Medroxyprogesterone acetate.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Medroxyprogesterone acetate.
MitotaneThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Modafinil.
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medroxyprogesterone acetate.
NafcillinThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Nafcillin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Medroxyprogesterone acetate.
NefazodoneThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Nilotinib.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Medroxyprogesterone acetate.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Medroxyprogesterone acetate.
OlaparibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Olaparib.
OsimertinibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Osimertinib.
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Medroxyprogesterone acetate.
OuabainOuabain may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medroxyprogesterone acetate.
PalbociclibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Palbociclib.
PentobarbitalThe metabolism of Medroxyprogesterone acetate can be increased when combined with Pentobarbital.
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medroxyprogesterone acetate.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Medroxyprogesterone acetate.
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Medroxyprogesterone acetate.
PhenobarbitalThe metabolism of Medroxyprogesterone acetate can be increased when combined with Phenobarbital.
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Medroxyprogesterone acetate.
PhenytoinThe metabolism of Medroxyprogesterone acetate can be increased when combined with Phenytoin.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Medroxyprogesterone acetate.
PosaconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Medroxyprogesterone acetate.
PrimidoneThe metabolism of Medroxyprogesterone acetate can be increased when combined with Primidone.
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Medroxyprogesterone acetate.
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Medroxyprogesterone acetate.
RanolazineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Ranolazine.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Medroxyprogesterone acetate.
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Medroxyprogesterone acetate.
RifabutinThe metabolism of Medroxyprogesterone acetate can be increased when combined with Rifabutin.
RifampicinThe metabolism of Medroxyprogesterone acetate can be increased when combined with Rifampicin.
RifapentineThe metabolism of Medroxyprogesterone acetate can be increased when combined with Rifapentine.
RitonavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ritonavir.
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medroxyprogesterone acetate.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Medroxyprogesterone acetate.
SaquinavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Medroxyprogesterone acetate.
SildenafilThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Simeprevir.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Medroxyprogesterone acetate.
St. John's WortThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Medroxyprogesterone acetate.
TelaprevirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Telithromycin.
TiclopidineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Medroxyprogesterone acetate.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Medroxyprogesterone acetate.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Medroxyprogesterone acetate.
UlipristalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Ulipristal.
VenlafaxineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Medroxyprogesterone acetate.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Medroxyprogesterone acetate.
VoriconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Voriconazole.
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Medroxyprogesterone acetate.
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Medroxyprogesterone acetate.
ZiprasidoneThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Ziprasidone.
Food Interactions
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Risch HA, Bale AE, Beck PA, Zheng W: PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1738-41. [PubMed:16985038 ]
  2. Madauss KP, Stewart EL, Williams SP: The evolution of progesterone receptor ligands. Med Res Rev. 2007 May;27(3):374-400. [PubMed:17013809 ]
  3. Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol. 2006 Oct;26(20):7632-44. [PubMed:17015480 ]
  4. Wu HB, Fabian S, Jenab S, Quinones-Jenab V: Progesterone receptors activation after acute cocaine administration. Brain Res. 2006 Dec 18;1126(1):188-92. Epub 2006 Nov 15. [PubMed:17109827 ]
  5. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007 Feb;21(2):359-75. Epub 2006 Nov 30. [PubMed:17138644 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Jain JK, Li A, Yang W, Minoo P, Felix JC: Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. Fertil Steril. 2007 Jan;87(1):8-23. Epub 2006 Nov 7. [PubMed:17094978 ]
  2. Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES: Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14. [PubMed:17103262 ]
  3. Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA: Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006;4 Suppl 1:S9. [PubMed:17118173 ]
  4. Yuri T, Tsukamoto R, Uehara N, Matsuoka Y, Tsubura A: Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. In Vivo. 2006 Nov-Dec;20(6B):829-36. [PubMed:17203775 ]
  5. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8. [PubMed:17415709 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhang JW, Liu Y, Zhao JY, Wang LM, Ge GB, Gao Y, Li W, Liu HT, Liu HX, Zhang YY, Sun J, Yang L: Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos. 2008 Nov;36(11):2292-8. doi: 10.1124/dmd.108.022525. Epub 2008 Aug 25. [PubMed:18725509 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid delta-isomerase activity
Specific Function:
3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system plays a crucial role in the biosynthesis of all classes of hormonal steroids.
Gene Name:
HSD3B2
Uniprot ID:
P26439
Molecular Weight:
42051.845 Da
References
  1. Lee TC, Miller WL, Auchus RJ: Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. J Clin Endocrinol Metab. 1999 Jun;84(6):2104-10. [PubMed:10372718 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:26